The internet has finally taken over the SfN conferences, and there is hardly anyone who doesn't have a smartphone/iPad in their hand at all times. Excellent apps help you to find your way quickly and easily, which is a must at a conference with more than 22,000 participants. But the technical innovation only shows that the conference is moving with the times. The essence today is still what its creators envisioned in 1971: neuroscience from A to Z.

Tetrabenazine, a VMAT-2 enzyme inhibitor, is used to treat sudden movements caused by neurodegenerative diseases called Huntington's disease and tardive dyskinesia, which are uncontrollable by the individual. The extent to which this drug inhibits the release of the monoamines noradrenaline, dopamine, and serotonin in different brain areas is not yet known. This is what a collaboration between the Sperlágh group and researchers at Richter Gedeon Nyrt led by Szilveszter E. Vizi investigated. The significance of the result is underlined by the fact that the work, first submitted by Pál Tod and with corresponding authorship by Professor Vizi, was published in the leading international journal of pharmacology.

"Autumn is here, it's here again", we could have said with Petőfi, and we could have agreed with the rest, that autumn is beautiful. The first day of our stay in Várgestes, 26 September, was so beautiful that you couldn't wish for a more beautiful day since the end of September. The main reason for our satisfaction, however, was that our Institute conference went very well!

The HUN-REN KOKI and the Weizmann Institute in Israel co-organised a two-day symposium at the KOKI, 28-29 October 2024, which contributed to the promotion of long-term joint neuroscience research between Hungary and Israel.